Literature DB >> 17068149

Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells.

Laurent David1, Christine Mallet, Sabine Mazerbourg, Jean-Jacques Feige, Sabine Bailly.   

Abstract

ALK1 is an endothelial-specific type I receptor of the TGFbeta receptor family whose heterozygous mutations cause hereditary hemorrhagic telangiectasia type 2. Although TGFbeta1 and TGFbeta3 have been shown to bind ALK1 under specific experimental conditions, they may not represent the physiological ligands for this receptor. In the present study, we demonstrate that BMP9 induces the phosphorylation of Smad1/5/8 in microvascular endothelial cells, and this phosphorylation lasts over a period of 24 hours. BMP9 also activates the ID1 promoter-derived BMP response element (BRE) in a dose-dependent manner (EC50 = 45 +/- 27 pg/mL), and this activation is abolished by silencing ALK1 expression or addition of ALK1 extracellular domain. Overexpression of endoglin increases the BMP9 response, whereas silencing of both BMPRII and ActRIIA expressions completely abolishes it. BMP10, which is structurally close to BMP9, is also a potent ALK1 ligand. Finally, we demonstrate that BMP9 and BMP10 potently inhibit endothelial cell migration and growth, and stimulate endothelial expression of a panel of genes that was previously reported to be activated by the constitutively active form of ALK1. Taken together, our results suggest that BMP9 and BMP10 are two specific ALK1 ligands that may physiologically trigger the effects of ALK1 on angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17068149     DOI: 10.1182/blood-2006-07-034124

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  280 in total

1.  BMP-9 balances endothelial cell fate.

Authors:  Rik Derynck; Rosemary J Akhurst
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-12       Impact factor: 11.205

Review 2.  Structural Biology and Evolution of the TGF-β Family.

Authors:  Andrew P Hinck; Thomas D Mueller; Timothy A Springer
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

3.  Endoglin Regulation of Smad2 Function Mediates Beclin1 Expression and Endothelial Autophagy.

Authors:  Christopher C Pan; Sanjay Kumar; Nirav Shah; Jeffrey C Bloodworth; Lukas J A C Hawinkels; Karthikeyan Mythreye; Dale G Hoyt; Nam Y Lee
Journal:  J Biol Chem       Date:  2015-04-30       Impact factor: 5.157

4.  Bone morphogenetic proteins.

Authors:  Dwight A Towler
Journal:  Blood       Date:  2009-09-03       Impact factor: 22.113

5.  BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer's disease.

Authors:  Rebecca M Burke; Timothy A Norman; Tarik F Haydar; Barbara E Slack; Susan E Leeman; Jan Krzysztof Blusztajn; Tiffany J Mellott
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

Review 6.  Biology of BMP signalling and cancer.

Authors:  M Blanco Calvo; V Bolós Fernández; V Medina Villaamil; G Aparicio Gallego; S Díaz Prado; E Grande Pulido
Journal:  Clin Transl Oncol       Date:  2009-03       Impact factor: 3.405

Review 7.  Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.

Authors:  Monika Spaczyńska; Susana F Rocha; Eduardo Oliver
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01

Review 8.  Vascular anomalies: from genetics toward models for therapeutic trials.

Authors:  Melanie Uebelhoer; Laurence M Boon; Miikka Vikkula
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

9.  Targeting NCK-Mediated Endothelial Cell Front-Rear Polarity Inhibits Neovascularization.

Authors:  Alexandre Dubrac; Gael Genet; Roxana Ola; Feng Zhang; Laurence Pibouin-Fragner; Jinah Han; Jiasheng Zhang; Jean-Léon Thomas; Alain Chedotal; Martin A Schwartz; Anne Eichmann
Journal:  Circulation       Date:  2015-12-09       Impact factor: 29.690

10.  A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.

Authors:  Laura W Goff; Roger B Cohen; Jordan D Berlin; Filippo G de Braud; Andrej Lyshchik; Cristina Noberasco; Francesco Bertolini; Marina Carpentieri; Corrado Gallo Stampino; Antonello Abbattista; Erjan Wang; Hossein Borghaei
Journal:  Clin Cancer Res       Date:  2015-12-11       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.